undamentalytics Newsletter
Sign in

Koninklijke Philips NV (PHG) stock

Add to watchlist

Add holding +

NYSE: PHG NYSE Health Care Equipment Next results ~November 3, 2026

B Fundamentals grade

Koninklijke Philips NV is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$19

Price-to-earnings vs peers

Base case. Range ~$19–$36. Earnings per share times peers' typical (harmonic-mean) price-to-earnings.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Koninklijke Philips NV valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds258 adding, 109 cuttingOf 30 active managers that changed their stake, 10 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Koninklijke Philips NV files

Where Koninklijke Philips NV stands after its latest Filing

Revenue for the twelve months was $20.2bn, up 3.4% on a year earlier, against a decline of 0.8% a quarter earlier. Operating margin widened to 8.0% from 3.2%. The diluted share count is up 3.1% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 2 of our 6 financial-health checks. Our price-to-earnings vs peers value is $18.59 a share, against a share price of $26.92.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Where it stands out: stock pay as % of revenue of 0.8% ranks 3 of 123 health care equipment companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 51% in the quarter to 2026-06-30, the 4th beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Growth speeding up. The growth rate is 4.2 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 5.0 points on a year ago.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Share dilution. Diluted shares rose 3.1% in a year.
  • Below peers: days sales outstanding. Days sales outstanding of 75 days ranks 89 of 118 health care equipment companies we cover (median 57 days).

Latest results

Earnings per share
$0.56 against an average estimate of $0.37: beat by 51.3%
Next report
November 3, 2026

Koninklijke Philips NV's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.5%
  • 1 week+3.8%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$20.2B
Operating margin
8.0%
Net margin
5.0%
EPS (TTM, diluted)
$1.05

Growth

Revenue growth
+3.4%
Change in growth rate
+4.2 pts
Share count change
+3.1%

Cash

Stock pay % of revenue
0.8%

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for PHG from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Koninklijke Philips NV valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Koninklijke Philips NV as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$19 ~$20–$36 Primary model, counts double
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$4.2 ~$2.6–$6.9 Left out: out of range vs price (0.15x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity below long-run growth
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: earnings are positive: price-to-earnings is the better measure
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$19 ~$19–$36 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Koninklijke Philips NV with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, before the open.

Analysts' consensus

No analyst estimates are published for Koninklijke Philips NV: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.37 $0.56 +51.3%
Mar 2026 $0.19 $0.27 +42.8%
Dec 2025 $0.50 $0.71 +41.8%
Sept 2025 $0.32 $0.41 +30.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Nov 2026
Buy240%
Hold360%
Sell00%

Monthly trend

  1. Nov 2026235
  2. Oct 2026235

Counts of recommendations published by analysts covering Koninklijke Philips NV, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
—
of tradable shares
Days to cover
2.52
at average volume
Short interest, 1 month
+7%
to October 15, 2026
Held by institutions
5%
of shares
Held by insiders
0.0%
of shares
Employees
63,670
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Koninklijke Philips NV in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Koninklijke Philips NV
$18B $19B $20B $21B $22B FY15 Q4 FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue (TTM), FY15 Q4: $18.6B Revenue (TTM), FY16 Q4: $19.3B Revenue (TTM), FY17 Q4: $20.1B Revenue (TTM), FY18 Q4: $21.4B Revenue (TTM), FY19 Q4: $19.2B Revenue (TTM), FY20 Q4: $19.8B Revenue (TTM), FY21 Q4: $20.3B Revenue (TTM), FY22 Q4: $18.8B Revenue (TTM), FY23 Q4: $19.7B Revenue (TTM), FY24 Q4: $19.5B Revenue (TTM), FY25 Q4: $20.2B $20.2B

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY15 Q4 $18.6B
FY16 Q4 $19.3B
FY17 Q4 $20.1B
FY18 Q4 $21.4B
FY19 Q4 $19.2B
FY20 Q4 $19.8B
FY21 Q4 $20.3B
FY22 Q4 $18.8B
FY23 Q4 $19.7B
FY24 Q4 $19.5B
FY25 Q4 $20.2B
Revenue growth, TTM YoY Koninklijke Philips NV
-15% -10% -5% 0% 5% 10% FY16 Q4 FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Revenue growth, TTM YoY, FY16 Q4: 3.4% Revenue growth, TTM YoY, FY17 Q4: 4.2% Revenue growth, TTM YoY, FY18 Q4: 6.6% Revenue growth, TTM YoY, FY19 Q4: -10.4% Revenue growth, TTM YoY, FY20 Q4: 2.9% Revenue growth, TTM YoY, FY21 Q4: 2.7% Revenue growth, TTM YoY, FY22 Q4: -7.5% Revenue growth, TTM YoY, FY23 Q4: 4.6% Revenue growth, TTM YoY, FY24 Q4: -0.8% Revenue growth, TTM YoY, FY25 Q4: 3.4% 3.4%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY16 Q4 3.4%
FY17 Q4 4.2%
FY18 Q4 6.6%
FY19 Q4 -10.4%
FY20 Q4 2.9%
FY21 Q4 2.7%
FY22 Q4 -7.5%
FY23 Q4 4.6%
FY24 Q4 -0.8%
FY25 Q4 3.4%
Operating margin (TTM) Koninklijke Philips NV
-10% -5% 0% 5% 10% FY15 Q4 FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Operating margin (TTM), FY15 Q4: 3.9% Operating margin (TTM), FY16 Q4: 8.4% Operating margin (TTM), FY17 Q4: 8.5% Operating margin (TTM), FY18 Q4: 9.5% Operating margin (TTM), FY19 Q4: 8.0% Operating margin (TTM), FY20 Q4: 7.3% Operating margin (TTM), FY21 Q4: 3.2% Operating margin (TTM), FY22 Q4: -8.6% Operating margin (TTM), FY23 Q4: -0.6% Operating margin (TTM), FY24 Q4: 2.9% Operating margin (TTM), FY25 Q4: 8.0% 8.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY15 Q4 3.9%
FY16 Q4 8.4%
FY17 Q4 8.5%
FY18 Q4 9.5%
FY19 Q4 8.0%
FY20 Q4 7.3%
FY21 Q4 3.2%
FY22 Q4 -8.6%
FY23 Q4 -0.6%
FY24 Q4 2.9%
FY25 Q4 8.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F, 20-F/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Koninklijke Philips NV took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $20.2B
  2. Cost of revenue $11.1B · 54.8%
  3. Gross profit $9.1B · 45.2%
  4. Research and development $1.9B · 9.5%
  5. Other operating costs $5.6B · 27.7%
  6. Operating income $1.6B · 8.0%
  7. Income tax $319M · 1.6%
  8. Interest and other $279M · 1.4%
  9. Net income $1B · 5.0%

Shares of revenue. Source: Koninklijke Philips NV's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 18.6 19.3 20.1 21.4 19.2 19.8 20.3 18.8 19.7 19.5 20.2
Gross profit 8.0 8.8 9.2 10.1 8.8 8.9 8.5 7.6 8.1 8.4 9.1
EBITDA 1.8 2.7 2.9 3.3 3.0 3.1 2.2 0.1 1.2 2.1 2.9
Operating income 0.7 1.6 1.7 2.0 1.5 1.4 0.7 −1.6 −0.1 0.6 1.6
Net income 0.7 1.6 1.9 1.3 1.3 1.4 3.9 −1.7 −0.5 −0.8 1.0
Diluted EPS $0.75 $1.73 $1.98 $1.35 $1.40 $1.47 $4.14 −$1.78 −$0.53 −$0.81 $1.05
Growth (year on year)
Revenue — +3.4% +4.2% +6.6% −10.4% +2.9% +2.7% −7.5% +4.6% −0.8% +3.4%
EBITDA — +49.4% +6.3% +15.5% −8.6% +2.6% −28.6% −96.5% — +67.5% +38.8%
Operating income — +122.0% +5.8% +18.5% −24.7% −5.7% −54.6% −346.2% — — +181.3%
Net income — +131.5% +16.8% −31.2% +1.4% +3.7% +189.9% −143.1% — — —
Diluted EPS — +128.9% +14.5% −31.9% +3.9% +5.2% +181.3% −143.0% — — —
Margins
Gross margin 42.9% 45.6% 46.0% 47.2% 46.1% 45.2% 41.8% 40.4% 41.0% 43.1% 45.2%
EBITDA margin 9.7% 14.0% 14.3% 15.5% 15.8% 15.7% 10.9% 0.4% 6.3% 10.6% 14.3%
Operating margin 3.9% 8.4% 8.5% 9.5% 8.0% 7.3% 3.2% −8.6% −0.6% 2.9% 8.0%
Net margin 3.7% 8.3% 9.3% 6.0% 6.8% 6.9% 19.3% −9.0% −2.6% −3.9% 5.0%
Cash flow
Capital spending −0.5 −0.4 0.5 0.5 0.5 0.6 0.5 0.5 0.4 0.3 0.3
Stock-based pay — — 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2
Balance sheet
Cash 1.9 2.5 2.3 1.9 1.6 3.9 2.6 1.3 2.1 2.5 3.3
Total debt 6.3 5.9 5.7 5.5 6.1 8.5 7.9 8.8 8.5 7.9 9.5
Net debt (negative = net cash) 4.3 3.5 3.3 3.6 4.5 4.5 5.3 7.5 6.4 5.4 6.2
Diluted shares 916m 918m 929m 941m 921m 908m 944m 952m 948m 933m 963m
Returned to shareholders
Buybacks −0.6 −0.7 0.7 1.2 1.5 0.4 1.9 0.2 0.7 0.4 0.0
Total returned −0.6 −0.7 0.7 1.2 1.5 0.4 1.9 0.2 0.7 0.4 0.0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 6 checks passed · December 31, 2025
What it owns · $31.6bn
Short-term assets $11.7bnLonger-term assets $20.0bn
What it owes, and who funded it · $31.6bn
Short-term liabilities $8.8bnLonger-term liabilities $9.9bnShareholders' equity $12.9bn
  • Short-term assets cover short-term liabilities $11.7bn of assets due within a year against $8.8bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $11.7bn short-term assets against $9.9bn of longer-dated liabilities.
  • More cash than debt $3.3bn of cash against $9.5bn of debt.
  • Debt below 40% of shareholders' equity Debt is 74% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 48% to 74% over five years.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of $1.6bn against $326m of interest.

From Koninklijke Philips NV's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2025 Q4 TTM
Buybacks (TTM)
$0
Buybacks, last 3 fiscal years
$1.2B
Diluted share count
+3.1%
year over year
R&D spending
9.5%
of revenue
Days sales outstanding
75 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated PHG BSX GEHC SYK BAX ISRG Median
Revenue, last 12 months $20.2bn $21.1bn $21.6bn $26.3bn $11.6bn $11.6bn $99m
Revenue growth, last 12 months 3.4% 8.9% 6.9% 7.9% 5.3% 20.5% 9.2%
Revenue growth, 3-year average — 15.3% 3.9% 9.8% 0.7% 19.1% 13.5%
Revenue growth, latest quarter — 1.4% 7.2% 7.6% 5.0% 21.7% 10.2%
Gross margin 45.2% 69.1% 39.9% 65.3% 30.1% 67.2% 61.2%
Operating margin 8.0% 18.7% 13.3% 20.7% −1.9% 28.4% −8.5%
Operating margin, 3-year average 6.6% 17.4% 13.2% 18.5% 1.7% 28.0% −17.9%
Net margin 5.0% 16.6% 10.0% 13.8% −6.2% 25.5% −12.0%
Cash from operations / revenue — 20.1% 11.2% 20.7% 14.1% 35.3% −1.9%
Free-cash-flow margin — 15.8% 8.7% 17.4% 8.4% 31.1% −3.9%
Free-cash-flow margin, 3-year average — 16.4% 8.1% 16.2% 4.1% 20.7% −7.0%
Stock pay / revenue 0.8% 1.5% 0.7% 1.0% 0.9% 7.3% 6.1%
Change in share count 3.1% −0.9% −0.6% −0.1% 0.7% −1.7% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 3.4% 9.1% 91 of 129
Change in growth rate Growth +4.2pp -0.6pp 26 of 129
Gross margin Profitability 45.2% 61.9% 91 of 123
Operating margin Profitability 8.0% -8.3% 34 of 132
Net margin Profitability 5.0% -12.0% 39 of 133
Stock pay as % of revenue Cash generation 0.8% 6.1% 3 of 123
Long-term debt as % of assets Balance sheet 25.7% 24.2% 47 of 87
Change in share count Balance sheet 3.1% 3.3% 56 of 115
Days sales outstanding Balance sheet 75 days 57 days 89 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$1.4B
Institutions reporting
362
Shares held vs prior quarter
▲ 0.9%
Positions opened / closed
55 / 31

Top buyers and sellers, Q2 2026: 258 institutions bought and 109 sold ; the biggest buyer was Causeway Capital Management LLC (+606K shares) and the biggest seller Fiduciary Management Inc (−1.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Mondrian Investment Partners Ltd $219M 8.1M 15.7% ▲ 3.5%
Dimensional Fund Advisors LP $118M 4.3M 8.4% ▼ 1.0%
Fiduciary Management Inc $94.1M 3.5M 6.7% ▼ 30.5%
Causeway Capital Management LLC $83.3M 3.1M 5.9% ▲ 24.7%
Morgan Stanley $79.8M 2.9M 5.7% ▲ 5.7%
FMR LLC $72.2M 2.7M 5.2% ▼ 2.6%
Brandes Investment Partners, LP $60.1M 2.2M 4.3% ▲ 11.1%
Northern Trust Corp $56.7M 2.1M 4.1% ▲ 0.9%
Blackrock, Inc. $54.3M 2.0M 3.9% ▲ 36.9%
Envestnet Asset Management Inc $35.3M 1.3M 2.5% ▲ 2.0%
UBS Am, A Distinct Business Unit Of UBS Asset Management Americas LLC $25.7M 944K 1.8% ▼ 3.4%
Goldman Sachs Group Inc $24.8M 912K 1.8% ▼ 15.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Koninklijke Philips NV's complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 26 trades and filings

No trades in Koninklijke Philips NV disclosed in the last 12 months; 26 earlier trades on record.

  • Earl Blumenauer(D-OR 3):Purchase, $1,001 - $15,000, traded February 12, 2024, filed March 2, 2024
  • Daniel S. Goldman(D-NY 10):Sale (full), $1,001 - $15,000, traded July 10, 2023, filed August 13, 2023
  • Earl Blumenauer(D-OR 3):Purchase, $1,001 - $15,000, traded July 27, 2022, filed August 8, 2022

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Koninklijke Philips NV was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Koninklijke Philips NV in brief

What does Koninklijke Philips NV do?
Koninklijke Philips NV is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Koninklijke Philips NV's stock ticker?
Koninklijke Philips NV trades under the ticker PHG on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Koninklijke Philips NV's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Koninklijke Philips NV reported revenue of $20.2B, 3.4% higher than a year earlier, according to its SEC filings.
Who are Koninklijke Philips NV's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Mondrian Investment Partners Ltd, Dimensional Fund Advisors LP and Fiduciary Management Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Koninklijke Philips NV buying back stock, and does it pay a dividend?
Koninklijke Philips NV spent $0 on share repurchases over the trailing twelve months, and its diluted share count still rose 3.1% over the year.
How much debt does Koninklijke Philips NV have?
Koninklijke Philips NV's debt-to-equity ratio is 73.8%, from its latest balance sheet (48.1% five years earlier). The financial health section below sets out its other solvency checks.
Who are Koninklijke Philips NV's competitors?
In our Health Care Equipment peer group, the companies closest to Koninklijke Philips NV are Boston Scientific, GE HealthCare, Stryker Corporation, Baxter International and Intuitive Surgical. The side-by-side comparison below sets their revenue, margins and growth against Koninklijke Philips NV's.
When is Koninklijke Philips NV's next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Koninklijke Philips NV announces its own schedule.